Third Time Lucky? Sun’s Ampyra Generic Appears On Course To Indian Debut
Executive Summary
Amid all the heat around the patents for Acorda Therapeutics’ multiple sclerosis therapy Ampyra (dalfampridine) in the US, Sun Pharma appears to have received a key approval for its generic version of the product in India setting the stage for a potential launch in the country.